Lead Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Presence of BRAF V600E mutation in tumor tissue
•Histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC
•At least one measurable lesion as defined by RECIST v1.1
•Patients must have progressed during or after at least one previous systemic, anti-cancer treatment for locally advanced or metastatic NSCLC.
•Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-2

•Patients with symptomatic Central Nervous System (CNS) metastases
•History of leptomeningeal metastases
•Prior therapy with a BRAF inhibitor
•Patients taking prohibited medication listed in the protocol
•Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.
•Impaired cardiovascular function or clinically significant cardiovascular diseases
•Pregnant or lactating women or woman of childbearing potential